Seagen announces updated results from pivotal her2climb trial evaluating tukysa® (tucatinib) in patients with her2-positive breast cancer with brain metastases

Bothell, wash.--(business wire)-- #sabcs2021--seagen announces updated results from pivotal trial evaluating tukysa® (tucatinib) in patients with her2-positive breast cancer with brain metastases

SGEN Ratings Summary

SGEN Quant Ranking